When United States. Food and Drug Administration approved two gene therapies for sickle cell disease?

Correct Answer: C. 8 December 2023

The U.S. Food and Drug Administration (FDA) on  8 December 2023 approved two gene therapies for sickle cell disease, making one of them the first treatment in the United States based on the Nobel Prize-winning CRISPR gene editing technology.
Casgevy, developed by partners Vertex Pharmaceuticals (VRTX.O) and CRISPR Therapeutics (CRSP.BN), and bluebird bio’s (BLUE.O) Lyfgenia were approved for people aged 12 years and older.